Related Experiment Video

Updated: Mar 25, 2026

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

6.2K

Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition

Claire F Friedman1, Michael A Postow2

  • 1Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USA. friedmac@mskcc.org.

Current Oncology Reports
|February 29, 2016
PubMed

Keywords:
BiomarkersCTLA-4Checkpoint blockadeImmunotherapyIpilimumabMelanomaNeoantigensNivolumabPD-1PD-L1Pembrolizumab

More Related Videos

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.7K
Predictive Immune Modeling of Solid Tumors08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.7K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K